Japanese encephalitis virus vaccine

(redirected from Ixiaro)

Japanese encephalitis virus vaccine

(Ja-pan-ees en-se-fa-li-tes vak-seen) ,

Ixiaro

(trade name)

Classification

Therapeutic: vaccines immunizing agents
Pregnancy Category: B

Indications

Active immunization against disease caused by Japanese encephalitis virus (JEV) in persons ≥17 yr.

Action

An inactive form of the virus induces antibodies that neutralize live JEV.

Therapeutic effects

Prevention of disease caused by JEV.

Pharmacokinetics

Absorption: Absorption follows intramuscular administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody production)

ROUTEONSETPEAKDURATION
IMunknownwithin 10 daysunknown

Contraindications/Precautions

Contraindicated in: Serious hypersensitivity to a previous dose; Serious hypersensitivity to protamine.
Use Cautiously in: Immunocompromised patients (may have ↓ response); Obstetric / Lactation: Safety and effectiveness not established; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)

Local

  • pain (most frequent)
  • tenderness (most frequent)
  • edema
  • pruritus

Musculoskeletal

  • myalgia (most frequent)

Interactions

Drug-Drug interaction

Concurrent use of immunosuppressives including antineoplastics and corticosteroids may ↓ antibody reponse and ↑ risk of adverse reactions.

Route/Dosage

Intramuscular (Adults ≥17 yr) 0.5 mL, repeated 28 days later; series completed at least 1 wk prior to potential exposure to JEV.

Availability

Suspension for injection (contains protamine): 0.5 mL single dose syringes

Nursing implications

Nursing assessment

  • Determine if patient has had reactions to previous vaccines.
  • Obtain temperature. Vaccine should not be administered to patients with fever >100°F.

Potential Nursing Diagnoses

Risk for infection (Indications)

Implementation

  • Immunization is administered in 2 doses, 28 days apart, completed at least 1 wk prior to exposure to JEV.
  • Intramuscular: Store in refrigerator; clear liquid with white precipitation may form during storage. Shake syringe well to obtain a white, opaque, homogenous suspension. Do not administer if discolored or contains particulate matter. Inject into deltoid; do not give intravenously, intradermally or subcutaneously.

Patient/Family Teaching

  • Inform patient of the purpose of vaccine and that vaccine is non-infectious. If second dose is missed, contact health care professional to determine when to receive second dose. Maximum protection is not achieved until 1 wk after second dose. Advise patient to read Patient Information Sheet prior to vaccination.
  • Advise patient of precautions to take to reduce exposure to mosquito bites transmitting virus (adequate clothing, use of repellents, mosquito nets). Vaccine may not fully protect everyone who gets the vaccine, does not protect against other types of encephalitis or other diseases transmitted by mosquito bites.
  • Advise patient to tell health care professional what medications they are taking.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

Evaluation/Desired Outcomes

  • Protection against Japanese Encephalitis Virus.
References in periodicals archive ?
34m) thanks to higher profitability of the Ixiaro vaccine and merger synergies.
Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, Ixiaro (IC51), in 6 months of follow-up.
The JE-VC vaccine, manufactured as IXIARO, was licensed for use in adults in the United States, Europe, and Australia in 2009.
However, JEEV / Ixiaro would have the advantage of prior FDA approval making it a more confident choice for travelers from Europe/ America.
ADPnews) - May 27, 2011 - Austrian vaccine maker Intercell AG (WBAG:ICLL) is recalling batch JEV09L37 of the Ixiaro vaccine throughout the EU, European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) said today.
In March 2009, the Food and Drug Administration licensed a new Japanese encephalitis vaccine, Intercell's Ixiaro (distributed by Novartis), for use in adults aged 17 years and older.
market: Ilaris, Reclast, Afinitor, Ixiaro, Exforge HCT, and Coartem.
The vaccine, called Ixiaro, prevents Japanese encephalitis (JE), which causes 10,000 to 15,000 deaths each year.
The vaccine is marketed as Ixiaro by Intercell Biomed, a Scottish company, and is distributed in the United States by Novartis.
Intercell's return to profitability largely depends on its most important product at the moment, the Ixiaro vaccine against Japanese encephalitis.
Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to update its previous recommendations and include IXIARO, a new Japanese Encephalitis (JE) vaccine for travelers to countries in Asia where the disease is endemic, as well as Americans living in such high-risk areas.